急性胸痛中肌钙蛋白风险分层并指导计算机断层冠状动脉血管造影有效使用(TARGET-CTCA):一项随机对照试验
TARGET-CTCA是一项多中心前瞻性随机开放标签盲终点平行组事件驱动试验,旨在研究对疑似急性冠脉综合征且已排除心肌梗死、肌钙蛋白浓度处于中间范围(5 ng/L至第99百分位上限参考限)的患者,门诊计算机断层冠状动脉血管造影(CTCA)联合标准治疗能否降低后续心肌梗死或心源性死亡。计划招募2270例患者,以90%把握度和双侧P值0.05检测主要终点40%的相对风险降低,随访至标准治疗组累积97例主要结局事件,估计中位随访36个月。
要点
- 高危肌钙蛋白可识别未来心脏事件风险增加的患者。
- 试验纳入已排除心肌梗死且肌钙蛋白中间范围的患者。
- 主要终点为心肌梗死或心源性死亡。
核心结论
- 该随机对照试验将确定高敏肌钙蛋白指导的CTCA能否改善急诊就诊且无心肌梗死患者的结局并减少后续主要不良心脏事件。
研究设计与样本
- TARGET-CTCA为多中心前瞻性随机开放标签盲终点平行组事件驱动试验。
- 已排除心肌梗死和明确替代诊断后,肌钙蛋白浓度处于中间范围(5 ng/L至第99百分位上限参考限)的参与者按1:1随机分配至门诊CTCA联合标准治疗组或单纯标准治疗组。
- 计划招募2270例患者,以90%把握度和双侧P值0.05检测主要终点40%的相对风险降低。
- 随访持续至标准治疗组累积97例主要结局事件,估计中位随访36个月。
主要发现
- 原文未报告试验结果。
关键数值与推荐
- 主要终点为心肌梗死或心源性死亡。
- 次要终点包括临床、以患者为中心、流程和成本效果终点。
- 肌钙蛋白中间范围定义为5 ng/L至第99百分位上限参考限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The majority of patients with suspected acute coronary syndrome presenting to the emergency department will be discharged once myocardial infarction has been ruled out, although a proportion will have unrecognised coronary artery disease. In this setting, high-sensitivity cardiac troponin identifies those at increased risk of future cardiac events. In patients with intermediate cardiac troponin concentrations in whom myocardial infarction has been ruled out, this trial aims to investigate whether outpatient computed tomography coronary angiography (CTCA) reduces subsequent myocardial infarction or cardiac death. METHODS: TARGET-CTCA is a multicentre prospective randomised open label with blinded endpoint parallel group event driven trial. After myocardial infarction and clear alternative diagnoses have been ruled out, participants with intermediate cardiac troponin concentrations (5 ng/L to 99th centile upper reference limit) will be randomised 1:1 to outpatient CTCA plus standard of care or standard of care alone. The primary endpoint is myocardial infarction or cardiac death. Secondary endpoints include clinical, patient-centred, process and cost-effectiveness. Recruitment of 2270 patients will give 90% power with a two-sided P value of 0.05 to detect a 40% relative risk reduction in the primary endpoint. Follow-up will continue until 97 primary outcome events have been accrued in the standard care arm with an estimated median follow-up of 36 months. DISCUSSION: This randomised controlled trial will determine whether high-sensitivity cardiac troponin-guided CTCA can improve outcomes and reduce subsequent major adverse cardiac events in patients presenting to the emergency department who do not have myocardial infarction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03952351. Registered on May 16, 2019.
引用
- Lee KK, Lowe D, O'Brien R, et al. Troponin in acute chest pain to risk stratify and guide effective use of computed tomography coronary angiography (TARGET-CTCA): a randomised controlled trial. Trials. 2023. PMID: 37312104. doi:10.1186/s13063-023-07431-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。